BICO Group AB (publ) (CLLKF) Research

BICO Group AB (publ) is a global bio-convergence enterprise, conducting operations across North America, Europe, Asia, and other international markets. Its business is structured into two main divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions segment delivers a range of advanced equipment, including 3D bioprinters, hybrid microscopy systems, single-cell dispensing instruments, and liquid handling devices. This division also supplies essential consumables such as bioinks, reagents, microscope lenses, software, printheads, and even 3D reconstructed human tissues, particularly for applications in regulatory testing. Furthermore, Laboratory Solutions offers specialized services like 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology, primarily serving pharmaceutical and biotechnology companies. Conversely, the Bioautomation segment caters to industrial customers with products focused on precision dispensing and innovative biosensor technology. It also provides sophisticated diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. Overall, BICO Group's offerings include comprehensive solutions for industrial ecosystems, tissue engineering, multi-omics analysis, cell line development, and diagnostics. Its primary clientele originates from the medical, pharmaceutical, and cosmetic sectors. Founded in 2016 and headquartered in Gothenburg, Sweden, the company was previously known as Cellink AB (publ) before officially changing its name to BICO Group AB (publ) in August 2021.

Open BICO Group AB (publ) (CLLKF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.